

PROXYMED INC /FT LAUDERDALE/

Form 8-K

June 22, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported):

**June 21, 2007**

**PROXYMED, INC.**

(Exact name of registrant as specified in its charter)

**Florida**

(State or other jurisdiction of  
incorporation)

**000-22052**

(Commission File No.)

**65-0202059**

(IRS Employer  
Identification No.)

**1854 Shackleford Court, Suite 200,  
Norcross, Georgia 30093-2924**

(Address of principal executive offices)

**(770) 806-9918**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement**

On June 21, 2007, ProxyMed, Inc. d/b/a MedAvant Healthcare Solutions (the Company ), and certain of its wholly owned subsidiaries, entered into an Omnibus Amendment (the Amendment ) to that certain Security and Purchase Agreement with Laurus Master Fund, Ltd. ( Laurus ) dated December 6, 2005 (the Loan Agreement ), to provide an additional \$3,000,000 in financing to the Company. In addition to this amount, Laurus will extend up to an additional \$1,200,000 to the Company in the event that certain conditions are met. In connection with the Amendment, the Company issued 572,727 shares of its common stock, par value \$0.001 per share (the Closing Shares ) to Laurus.

The Company intends to use the proceeds from the Amendment for continued working capital.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

See disclosure provided in Item 1.01 above.

**Item 3.02 Unregistered Sales of Equity Securities.**

In connection with the Amendment, the Company will issue the Closing Shares to Laurus. The Closing Shares will be issued pursuant to section 4(2) of the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibit.**

**(d) Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release of MedAvant dated June 22, 2007.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 22, 2007

**ProxyMed, Inc.**

/s/ John G. Lettko

John G. Lettko  
President and Chief Executive  
Officer